Initiate KOMET-017 Phase 3 trials in first-line NPM1-m and KMT2A-r AML
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- by 29 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate KOMET-017 Phase 3 registration-enabling trials in 1L NPM1-m and KMT2A-r intensive and non-intensive AML 2H 2025”
What we found
Evidence strength B What the grades mean
Kura Oncology and Kyowa Kirin announced first patient dosed in KOMET-017 Phase 3 trials in September 2025, within the 2H 2025 target.
-
B Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) Press release confirming first patient dosed in KOMET-017 Phase 3 trials
-
B Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results Lists KOMET-017 initiation as a completed 2025 milestone
-
B Kura Oncology Reports Third Quarter 2025 Financial Results Confirms KOMET-017 first patient dosed in September 2025
Checked 15 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-KURA-000219 · Corrections policy